Masashige Shinkai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masashige Shinkai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Kobayashi
Department of Biotechnology, School of Engineering, Nagoya University
10 shared publications- Hiroyuki Honda
Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
9 shared publications Akira Ito
Nagoya University
4 shared publicationsMitsugu Yanase
Department of Biotechnology, Graduate School of Engineering, Nagoya University
4 shared publicationsMasataka Suzuki
Department of Biotechnology, Graduate School of Engineering, Nagoya University
3 shared publicationsJun Yoshida
Department of Neurosurgery, Graduate School of Medicine, Nagoya University, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
2 shared publications
Latest Publications
- 5 July 2004
- Published by Springer Nature
- Vol. 91, 191-220
Functional Magnetic Particles for Medical Application
Magnetic particles for medical applications have been developed by many researchers. Since magnetic particles have unique magnetic features not present in other materials, they can be applied to special medical techniques. Separation, immunoassay, magnetic resonance imaging (MRI), drug delivery, and hyperthermia are enhanced by the use of magnetic particles. Magnetite cationic liposomes (MCLs), one of the groups of cationic magnetic particles, can be used as carriers to introduce DNA into cells since their positively charged surface associates with the negatively charged DNA. MCLs can also be used as heat mediators for cancer therapy. Magnetic particles conjugated with tumor-specific antibodies have enabled tumor-specific contrast enhancement in MRI. In addition, antibody-conjugated magnetic particles were shown to target renal cell carcinoma cells, and are applicable to the hyperthermic treatment of carcinomas. It was also found that the hyperthermic treatment using magnetic particles induced an antitumor immunity. Thus, the use of magnetic particles with their unique features will further improve medical techniques.
- 5 July 2004
- Published by Springer Nature
- Vol. 91, 191-220
Functional Magnetic Particles for Medical Application
Magnetic particles for medical applications have been developed by many researchers. Since magnetic particles have unique magnetic features not present in other materials, they can be applied to special medical techniques. Separation, immunoassay, magnetic resonance imaging (MRI), drug delivery, and hyperthermia are enhanced by the use of magnetic particles. Magnetite cationic liposomes (MCLs), one of the groups of cationic magnetic particles, can be used as carriers to introduce DNA into cells since their positively charged surface associates with the negatively charged DNA. MCLs can also be used as heat mediators for cancer therapy. Magnetic particles conjugated with tumor-specific antibodies have enabled tumor-specific contrast enhancement in MRI. In addition, antibody-conjugated magnetic particles were shown to target renal cell carcinoma cells, and are applicable to the hyperthermic treatment of carcinomas. It was also found that the hyperthermic treatment using magnetic particles induced an antitumor immunity. Thus, the use of magnetic particles with their unique features will further improve medical techniques.
- Open Access
- 25 March 2004
- Published by Springer Nature in BioMagnetic Research and Technology
- Vol. 2 (1) , 3
Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma
We have developed magnetite cationic liposomes (MCLs) and applied them to local hyperthermia as a mediator. MCLs have a positive charge and generate heat under an alternating magnetic field (AMF) by hysteresis loss. In this study, the effect of hyperthermia using MCLs was examined in an in vivo study of hamster osteosarcoma. MCLs were injected into the osteosarcoma and then subjected to an AMF. The tumor was heated at over 42°C, but other normal tissues were not heated as much. Complete regression was observed in 100% of the treated group hamsters, whereas no regression was observed in the control group hamsters. At day 12, the average tumor volume of the treated hamsters was about 1/1000 of that of the control hamsters. In the treated hamsters, no regrowth of osteosarcomas was observed over a period of 3 months after the complete regression. These results suggest that this treatment is effective for osteosarcoma.
- 25 March 2004
- Published by Springer Nature in BioMagnetic Research and Technology
- Vol. 2 (1) , 3
Open AccessHyperthermia using magnetite cationic liposomes for hamster osteosarcoma
We have developed magnetite cationic liposomes (MCLs) and applied them to local hyperthermia as a mediator. MCLs have a positive charge and generate heat under an alternating magnetic field (AMF) by hysteresis loss. In this study, the effect of hyperthermia using MCLs was examined in an in vivo study of hamster osteosarcoma. MCLs were injected into the osteosarcoma and then subjected to an AMF. The tumor was heated at over 42°C, but other normal tissues were not heated as much. Complete regression was observed in 100% of the treated group hamsters, whereas no regression was observed in the control group hamsters. At day 12, the average tumor volume of the treated hamsters was about 1/1000 of that of the control hamsters. In the treated hamsters, no regrowth of osteosarcomas was observed over a period of 3 months after the complete regression. These results suggest that this treatment is effective for osteosarcoma.
- Open Access
- 1 January 2002
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 18 (4) , 191-198
Magnetite Needle as Heating Mediator for Intracellular Hyperthermia of Tumor.
- 1 January 2002
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 18 (4) , 191-198
Open AccessMagnetite Needle as Heating Mediator for Intracellular Hyperthermia of Tumor.
- 1 January 2002
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 18 (1) , 33-41
Characteristics of Particulate Heating Mediator in RF Capacitive Heating.
- 1 January 2002
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 18 (1) , 33-41
Characteristics of Particulate Heating Mediator in RF Capacitive Heating.
- 1 January 2002
- Vol. 94 (6) , 606-13
Functional magnetic particles for medical application.
Magnetic particles for medical applications have been developed by many researchers. Since magnetic particles have unique magnetic features not present in other materials, they can be applied to special medical techniques. Separation, immunoassay, magnetic resonance imaging (MRI), drug delivery, and hyperthermia are enhanced by the use of magnetic particles. Magnetite cationic liposomes (MCLs), one of the group of cationic magnetic particles, can be used as carriers to introduce DNA into cells since their positively charged surface associates with the negatively charged DNA. They can also be used as heat mediators for cancer therapy. Magnetic particles conjugated with tumor-specific antibodies have enabled tumor-specific contrast enhancement in MRI. In addition, antibody-conjugated magnetic particles were shown to target renal cell carcinoma cells, and are applicable to the hyperthermic treatment of carcinomas. The use of magnetic particles with their unique features will further improve medical techniques.
- 1 January 2002
- Vol. 94 (6) , 606-13
Functional magnetic particles for medical application.
Magnetic particles for medical applications have been developed by many researchers. Since magnetic particles have unique magnetic features not present in other materials, they can be applied to special medical techniques. Separation, immunoassay, magnetic resonance imaging (MRI), drug delivery, and hyperthermia are enhanced by the use of magnetic particles. Magnetite cationic liposomes (MCLs), one of the group of cationic magnetic particles, can be used as carriers to introduce DNA into cells since their positively charged surface associates with the negatively charged DNA. They can also be used as heat mediators for cancer therapy. Magnetic particles conjugated with tumor-specific antibodies have enabled tumor-specific contrast enhancement in MRI. In addition, antibody-conjugated magnetic particles were shown to target renal cell carcinoma cells, and are applicable to the hyperthermic treatment of carcinomas. The use of magnetic particles with their unique features will further improve medical techniques.
- 1 December 2001
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 50 (10) , 515-522
Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia
Heat shock proteins are recognized as significant participants in immune reactions. In this study, we have demonstrated that the cell surface presentation of MHC class I antigen was increased in tandem with increased heat shock protein 70 (HSP70) expression and the immunogenicity of rat T-9 glioma cells was enhanced by hyperthermia. T-9 cells showed growth inhibition for 24 h after the heat treatment at 43 °C for 1 h in vitro, but then resumed a normal growth rate. HSP70 expression reached a maximum at 24 h after heating. Flow cytometric analysis revealed a significant increase in MHC class I antigen on the surface of the heated cells. The augmentation of MHC class I surface expression started 24 h after heating and reached a maximum 48 h after heating. The expression of other immunologic mediators, such as intracellular adhesion molecule-1 (ICAM-1) and MHC class II antigens, did not increase. In an in vivo experiment using immunocompetent syngeneic rats (F344), growth of the heated T-9 cells, with augmentation of MHC class I antigen surface expression, was significantly inhibited, while the cells grew progressively in nude rats (F344/N Jcl-rnu). Furthermore, compared with lymphocytes from non-immunized (PBS only injection) rats or rats injected with non-heated T-9 cells, the splenic lymphocytes of the rats in which the heated T-9 cells were injected displayed specific cytotoxicity against T-9 cells. These results suggest that HSP70 is an important modulator of tumor cell immunogenicity, and that hyperthermic treatment of tumor cells can induce the host antitumor immunity via the expression of HSP70. These results may benefit further efforts on developing novel cancer immunotherapies based on hyperthermia.
- 1 December 2001
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 50 (10) , 515-522
Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia
Heat shock proteins are recognized as significant participants in immune reactions. In this study, we have demonstrated that the cell surface presentation of MHC class I antigen was increased in tandem with increased heat shock protein 70 (HSP70) expression and the immunogenicity of rat T-9 glioma cells was enhanced by hyperthermia. T-9 cells showed growth inhibition for 24 h after the heat treatment at 43 °C for 1 h in vitro, but then resumed a normal growth rate. HSP70 expression reached a maximum at 24 h after heating. Flow cytometric analysis revealed a significant increase in MHC class I antigen on the surface of the heated cells. The augmentation of MHC class I surface expression started 24 h after heating and reached a maximum 48 h after heating. The expression of other immunologic mediators, such as intracellular adhesion molecule-1 (ICAM-1) and MHC class II antigens, did not increase. In an in vivo experiment using immunocompetent syngeneic rats (F344), growth of the heated T-9 cells, with augmentation of MHC class I antigen surface expression, was significantly inhibited, while the cells grew progressively in nude rats (F344/N Jcl-rnu). Furthermore, compared with lymphocytes from non-immunized (PBS only injection) rats or rats injected with non-heated T-9 cells, the splenic lymphocytes of the rats in which the heated T-9 cells were injected displayed specific cytotoxicity against T-9 cells. These results suggest that HSP70 is an important modulator of tumor cell immunogenicity, and that hyperthermic treatment of tumor cells can induce the host antitumor immunity via the expression of HSP70. These results may benefit further efforts on developing novel cancer immunotherapies based on hyperthermia.
- 1 January 2001
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 92 (6) , 598-601
Radiation-Inducible TNF-α Gene Expression under Stress-Inducible Promoter gadd 153 for Cancer Therapy
- 1 January 2001
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 92 (6) , 598-601
Radiation-Inducible TNF-α Gene Expression under Stress-Inducible Promoter gadd 153 for Cancer Therapy
- Open Access
- 1 January 2000
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 16 (2) , 91-98
Induction of TNF-.ALPHA. Gene Expression by Heat Inducible Promoter gadd 153.
We demonstrated the effectiveness of inducible expression of the TNF-α gene. The TNF-α gene located under the heat-inducible promoter, gadd 153, was introduced into the human glioma cell line, U251-SP. Without heat treatment, no cytotoxicity for the transfected cells was observed. When the transfected cells were treated with hyperthermia at 43°C for 1 h or 45°C for 1 h, inducible expression of the TNF-α gene was observed. The pattern of enhancement of the gene expression varied with temperature. The TNF-α production per cell on treatment at 43°C reached 4.3 times the basal level at one day after the heat treatment while the maximum production on treatment at 45°C was observed at 4 days after the heating. The cytotoxicity of the transfected cells treated at 43°C and at 45°C was 81% at 3 days after the heating and 99.9% at 4 days after the heating, respectively.
- 1 January 2000
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 16 (2) , 91-98
Open AccessInduction of TNF-.ALPHA. Gene Expression by Heat Inducible Promoter gadd 153.
We demonstrated the effectiveness of inducible expression of the TNF-α gene. The TNF-α gene located under the heat-inducible promoter, gadd 153, was introduced into the human glioma cell line, U251-SP. Without heat treatment, no cytotoxicity for the transfected cells was observed. When the transfected cells were treated with hyperthermia at 43°C for 1 h or 45°C for 1 h, inducible expression of the TNF-α gene was observed. The pattern of enhancement of the gene expression varied with temperature. The TNF-α production per cell on treatment at 43°C reached 4.3 times the basal level at one day after the heat treatment while the maximum production on treatment at 45°C was observed at 4 days after the heating. The cytotoxicity of the transfected cells treated at 43°C and at 45°C was 81% at 3 days after the heating and 99.9% at 4 days after the heating, respectively.
- Open Access
- 1 January 1999
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 15 (2) , 79-87
Enhancement of Uptake of Magnetoliposomes by Magnetic Force and Hyperthermic Effect on Tumor.
- 1 January 1999
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 15 (2) , 79-87
Open AccessEnhancement of Uptake of Magnetoliposomes by Magnetic Force and Hyperthermic Effect on Tumor.
- Open Access
- 1 January 1998
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 14 (1) , 15-22
Development of Anticancer Drugs- Encapsulated Magnetoliposome and Its Combination Effect of Hyperthermia and Chemotherapy.
- 1 January 1998
- Published by Japanese Society for Thermal Medicine in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
- Vol. 14 (1) , 15-22
Open AccessDevelopment of Anticancer Drugs- Encapsulated Magnetoliposome and Its Combination Effect of Hyperthermia and Chemotherapy.